Navigation Links
Codexis, Teva in Licensing Agreement Final
Date:1/7/2009

REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United States.

Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Codexis develops proprietary custom biocatalysts, and its technology contributes to lower pharmaceutical process development and manufacturing costs. Codexis technology is in use by leading drug companies worldwide. Financial terms were not disclosed.

"Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer. "Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals."

Codexis, Inc. is a clean technology company. Codexis develops biocatalysts used to create powerful, efficient and cleaner chemistry-based manufacturing processes in the life sciences, bioindustrial and chemical marketplaces. Codexis technology is used by global pharmaceutical companies for cost-effective manufacturing of human therapeutics and in the energy industry to enable next generation non-food biofuels. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit http://www.codexis.co
'/>"/>

SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
4. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
10. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
11. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Alliance, an,organization comprised of 12 of the nation,s best ... million Americans to exercise,their power over cancer by stepping ... Day through Father,s Day., The campaign, dubbed the ... activate Americans everywhere to take matters into their own,hands, ...
... Genaera,Corporation (Nasdaq: GENR ) today announced its financial ... for the quarter ended March 31,2008 was $4.3 million, or ... loss of $4.2 million, or $(0.24) per basic and diluted ... and development expenses for the quarter ended March,31, 2008 were ...
... ,Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... scheme of,arrangement proposed in a circular to shareholders ... a meeting convened by the Court and,held today., ... 2008, the High Court is expected to,approve the ...
Cached Biology Technology:Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research 2Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 2Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 3Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 5
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... The National Science Foundation has awarded Iowa State ... million grant to establish the NSF Engineering Research ... The award is part of the National ... Program. The third-generation Engineering Research Centers are designed ...
... utilize small, short-lived animals (insects, worms, mice) under ... parasites, superabundant food in the laboratory. Oddly ... such animals in their harsh, stressful natural environments. ... actually age much more slowly in captive luxury ...
... Bats, ability to echolocate may have evolved more than once, ... of London scientists. Species of bat with the ability ... tree of life - some are more related to their ... of whether echolocation in bats has evolved more than once, ...
Cached Biology News:Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 2Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 4Old before their time? Aging in flies under natural vs. laboratory conditions 2Molecular evolution is echoed in bat ears 2
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
... The GeneSwitch Cell Lines stably express ... Each cell line is functionally tested ... with the expression control vector pGene/V5-His/lacZ ... after treatment with mifepristone (Figure 1). ...
... 15-20 enhancements when used as directed, ... is designed to amplify the desired signal detected by ... proteins with low expression., Membrane Enhancement ... the membrane; 1x solution; 250 ml, ...
... library screening, optimal siRNA transfection ... verified for each cell type ... Transfection Optimization Kit, which was ... conditions in 96 well plates, ...
Biology Products: